Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.

Garon, Edward B; Visseren-Grul, Carla; Rizzo, Maria Teresa; Puri, Tarun; Chenji, Suresh; Reck, Martin

Garon, Edward B; Visseren-Grul, Carla; Rizzo, Maria Teresa; Puri, Tarun; Chenji, Suresh; Reck, Martin.

Afiliação

Garon EB; David Geffen School of Medicine, University of California, Los Angeles/Translational Research in Oncology-United States Network, Los Angeles, CA, United States.
Visseren-Grul C; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.
Rizzo MT; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.
Puri T; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.
Chenji S; Eli Lilly and Company, Bengaluru, Karnataka, India.
Reck M; Department of Thoracic Oncology, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Lung Clinic Grosshansdorf, Großhansdorf, Germany.

Front Oncol ; 13: 1247879, 2023.

Article em En | MEDLINE | ID: mdl-37731641

Palavras-chave

antiangiogenic therapy; docetaxel; immune checkpoint inhibitors; non-small cell lung cancer; ramucirumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Systematic_reviews Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google